Intratumor heterogeneity plays a critical role in cancer evolution and therapeutic outcomes. Understanding the genetic and mutational processes that shape the cancer genome is essential for precision medicine. Tumors accumulate somatic mutations through evolutionary processes, with some mutations being driver events that confer a selective advantage. However, not all mutations are present in every cancer cell, leading to intratumor heterogeneity. This heterogeneity can affect the effectiveness of targeted therapies, as many driver mutations may be present in only a subset of cells. The presence of subclonal mutations can also contribute to drug resistance and tumor progression. Genome instability processes, including mutational signatures, contribute to intratumor heterogeneity by generating a pool of mutations that can be selected for in different microenvironments. Mutational signatures, such as those associated with APOBEC cytidine deaminases, can influence the evolution of the cancer genome. Therapy can also induce genome instability, leading to mutations that may drive tumor progression. Additionally, clonal cooperation between subclones can promote tumor growth and survival. The evolutionary dynamics of tumors are complex, with processes such as branched evolution and parallel evolution playing a role in tumor development. Understanding the temporal sequence of mutations and their interactions is crucial for developing effective therapeutic strategies. Studies have shown that certain mutations, such as those in TP53, may be early events in cancer progression, while others may occur later. The clonal dominance of driver events can influence therapeutic outcomes, and subclonal mutations may complicate targeted therapy approaches. Immunotherapy offers a potential alternative to targeted therapy, as it may not rely on the clonality of a single target. Neoantigens generated by somatic mutations may be recognized by the immune system, improving prognosis. However, the effectiveness of immunotherapy may depend on the tumor's mutational burden and the inflammatory environment. Adaptive therapy, which focuses on controlling tumor growth rather than eliminating all cancer cells, may be a promising approach to managing intratumor heterogeneity. This strategy aims to prevent the outgrowth of resistant subclones by maintaining sensitive cells in the tumor population. Overall, understanding the evolutionary dynamics of tumors and the role of intratumor heterogeneity is essential for developing effective therapeutic strategies. Future research should focus on improving the detection and monitoring of subclonal events, as well as exploring new approaches to address the challenges posed by tumor heterogeneity.Intratumor heterogeneity plays a critical role in cancer evolution and therapeutic outcomes. Understanding the genetic and mutational processes that shape the cancer genome is essential for precision medicine. Tumors accumulate somatic mutations through evolutionary processes, with some mutations being driver events that confer a selective advantage. However, not all mutations are present in every cancer cell, leading to intratumor heterogeneity. This heterogeneity can affect the effectiveness of targeted therapies, as many driver mutations may be present in only a subset of cells. The presence of subclonal mutations can also contribute to drug resistance and tumor progression. Genome instability processes, including mutational signatures, contribute to intratumor heterogeneity by generating a pool of mutations that can be selected for in different microenvironments. Mutational signatures, such as those associated with APOBEC cytidine deaminases, can influence the evolution of the cancer genome. Therapy can also induce genome instability, leading to mutations that may drive tumor progression. Additionally, clonal cooperation between subclones can promote tumor growth and survival. The evolutionary dynamics of tumors are complex, with processes such as branched evolution and parallel evolution playing a role in tumor development. Understanding the temporal sequence of mutations and their interactions is crucial for developing effective therapeutic strategies. Studies have shown that certain mutations, such as those in TP53, may be early events in cancer progression, while others may occur later. The clonal dominance of driver events can influence therapeutic outcomes, and subclonal mutations may complicate targeted therapy approaches. Immunotherapy offers a potential alternative to targeted therapy, as it may not rely on the clonality of a single target. Neoantigens generated by somatic mutations may be recognized by the immune system, improving prognosis. However, the effectiveness of immunotherapy may depend on the tumor's mutational burden and the inflammatory environment. Adaptive therapy, which focuses on controlling tumor growth rather than eliminating all cancer cells, may be a promising approach to managing intratumor heterogeneity. This strategy aims to prevent the outgrowth of resistant subclones by maintaining sensitive cells in the tumor population. Overall, understanding the evolutionary dynamics of tumors and the role of intratumor heterogeneity is essential for developing effective therapeutic strategies. Future research should focus on improving the detection and monitoring of subclonal events, as well as exploring new approaches to address the challenges posed by tumor heterogeneity.